You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

VKORC1 polymorphisms and warfarin maintenance dose in population of Sakha (Yakuts)

Issue title: Special Issue: Evidence-Based Medicine: Achievements and Barriers

Article type: Abstract

Authors: Chertovskikh, Y.V.a; d | Malova, E.U.b; * | Maksimova, N.R.c | Popova, N.V.d | Sychev, D.A.e

Affiliations: [a] Ministry of Health of the Republic of Sakha (Yakutiya), Yakutsk, Russia | [b] I.M. Sechenov, First Moscow State Medical University, Moscow, Russia | [c] Laboratory of Genomic Medicine, Yakutsk, Russia | [d] Center for Personalized Medicine, Yakutsk, Russia | [e] Russian Medical Academy of Postgraduate Education, Moscow, Russia

Correspondence: [*] Corresponding author. E-mail: [email protected]

Keywords: Polymorphisms of the VKORC1 gene on maintenance warfarin dose in the population of sakha (yakuts)

DOI: 10.3233/JRS-150673

Journal: International Journal of Risk & Safety in Medicine, vol. 27, no. s1, pp. S17-S18, 2015

Published: 2015
Get PDF open access

Abstract

BACKGROUND:

Vitamin K antagonists are effective in the prevention and treatment of thromboembolic disorders. Warfarin is one of the most widely prescribed vitamin K antagonists in the world [1, 2]. It has a narrow therapeutic range and a given dose may result in a large inter-individual variation of response. Insufficient dose may fail to prevent thromboembolism, while an overdose increases the risk of bleeding. Patient-specific factors (e.g., age, body size, race, concurrent diseases, and medications) explain some of the variability in warfarin dosage, but genetic factors influencing warfarin response explain a significantly higher proportion of this variability [3]. Molecular analysis of the gene that encodes the target enzyme vitamin K epoxide reductase complex 1 (VKORC1) strongly suggests that its genetic variations greatly affect the individual response to oral anticoagulants [4–7].

OBJECTIVE:

To evaluate effects of VKORC1 polymorphisms on warfarin dose excess anticoagulation (INR >4.0) in the population of Sakha (S) patients.

METHODS:

53 patients (29-women, 24-men) with atrial fibrillation (68%), congestive heart failure (60%), hypertension (49%) and cardiac valve replacement (26%) were recruited. The age range was 26–80 years, with a mean age of 62.87 ± 12.57 years.

International normalized ratio and plasma warfarin concentrations were determined. Genotyping was carried out by RT-PCR (real-time PCR). The three genetic polymorphisms of the gene VKORC1 G3673A (rs9923231) were studied: normal (GG), heterozygous (GA) and homozygous (AA). Fisher exact probability test and chi-square test (with Yates correction) were applied to compare data among the AA and GG + GA groups; also Mann-Whitney test was used.

RESULTS:

The median maintenance daily dose of warfarin among AA carriers was 3.0 mg/day [1.25–7.5 mg], while in GG and GA patients it was 3.13 mg/day [1.88–7.92 mg]. The mean daily warfarin dosage was higher in GG and GA genotype carriers 4.05 mg/day (SD ± 1.7) than in patients with AA genotype 3.13 (SD ± 1.5). Differences are of borderline significance (p = 0.054). Of the 41 patients who required warfarin doses of less than 5 mg, 28 (63%) were found to be AA carriers and 14 (37%) were GG, GA carriers. Differences were not quite significant (p = 0.072). Among 31 homozygous polymorphism carriers 2 (4%) patients developed overanticoagulation (INR >4.0), while among 22 normal and heterozygous polymorphisms carriers only 3 (6%) patients developed overanticoagulation (INR >4.0). Differences were not statistically significant (p = 0.36).

CONCLUSIONS:

No significant association between VKORC1 polymorphisms and the frequency of excess anticoagulation (INR >4.0) was found. This may be explained by the number of cases included. AA polymorphisms compared to other polymorphisms shows borderline difference in the warfarin dose. The results can be used for the development of a pharmacogenetic-guided warfarin dosing algorithm.

Conflict of interest statement

None.

References

1 

Gage BF (2006) Pharmacogenetics-based coumarin therapy Hematology Am Soc Hematol Educ Program 67 473 10.1182/asheducation-2006.1.467

2 

Lee JS, Cheong HS, Kim LH, Kim JO, Seo DW, Kim YH (2013) Screening of Genetic Polymorphisms of CYP3A4 and CYP3A5 Genes Korean J Physiol Pharmacol 17: 6 479 484 10.4196/kjpp.2013.17.6.479

3 

Wadelius M, Pirmohamed M (2007) Pharmacogenetics of warfarin: Current status and future challenges Pharmacogenomics J 7: 2 99 111 10.1038/sj.tpj.6500417

4 

Wiwanitkit V (2006) Pharmacogenomic effect of cytochrome P450 2C9 polymorphisms in different populations Clin Appl Thromb Hemost 12: 219 222 10.1177/107602960601200211

5 

D’Andrea G, D’Ambrosio R, Margaglione M (2008) Oral anticoagulants: Pharmacogenetics. Relationship between genetic and non-genetic factors Blood Rev 22: 127 140 10.1016/j.blre.2007.11.004

6 

Mlynarsky L, Bejarano-Achache I, Muszkat M, Caraco Y (2012) Factor VII R353Q genetic polymorphism is associated with altered warfarin sensitivity among CYP2C9 *1/*1 carriers Eur J Clin Pharmacol 68: 617 627 10.1007/s00228-011-1143-z

7 

Yin T, Miyata T (2007) Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives Thromb Res 120: 1 10 10.1016/j.thromres.2006.10.021

Show more